about
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markersGuidelines for the diagnosis and treatment of cholangiocarcinoma: an updateRapid mapping of markers applying vectorette technology to YAC fragmentation allows easy assembly of a high-density STS bacterial clone contig spanning the markers D6S1260-D6S1918.Development of a decision support tool to facilitate primary care management of patients with abnormal liver function tests without clinically apparent liver disease [HTA03/38/02]. Abnormal Liver Function Investigations Evaluation (ALFIE).Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: a record-linkage population cohort study and decision analysis (ALFIE).Prediction of liver disease in patients whose liver function tests have been checked in primary care: model development and validation using population-based observational cohorts.Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.DNA vaccination: a potential weapon against infection and cancer.Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection.The utility of liver function tests for mortality prediction within one year in primary care using the algorithm for liver function investigations (ALFI).Biopsy-controlled liver fibrosis staging using the enhanced liver fibrosis (ELF) score compared to transient elastography.4-1BB ligand activates bystander dendritic cells to enhance immunization in transThe third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cellsPerformance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection.Management of hepatitis B in pregnant women and infants: a multicentre audit from four London hospitals.Screening and shouting about HCVTandem fusion of hepatitis B core antigen allows assembly of virus-like particles in bacteria and plants with enhanced capacity to accommodate foreign proteinsEvaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy.Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease.IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders.Performance of serum marker panels for liver fibrosis in chronic hepatitis C.Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity.Systematic review of the diagnostic performance of serum markers of liver fibrosis in alcoholic liver diseaseEnhanced liver fibrosis marker as a noninvasive predictor of mortality in HIV/hepatitis C virus-coinfected women from a multicenter study of women with or at risk for HIV.Isolated Hepatitis B Core Antibody Status Is Not Associated With Accelerated Liver Disease Progression in HIV/Hepatitis C CoinfectionA systematic review of the clinical validity and clinical utility of DNA testing for hereditary haemochromatosis type 1 in at-risk populations.A class C CpG toll-like receptor 9 agonist successfully induces robust interferon-alpha production by plasmacytoid dendritic cells from patients chronically infected with hepatitis C.Psychosocial aspects of DNA testing for hereditary hemochromatosis in at-risk individuals: a systematic review.Diagnostic strategies using DNA testing for hereditary haemochromatosis in at-risk populations: a systematic review and economic evaluation.T Cells Infiltrating Diseased Liver Express Ligands for the NKG2D Stress Surveillance System.Evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosis tests to detect significant fibrosis due to chronic hepatitis C.The immunology of coeliac disease.Treatment decisions and contemporary versus pending treatments for hepatitis C.Complexities of HCV management in the new era of direct-acting antiviral agents.Equilibrium contrast-enhanced CT imaging to evaluate hepatic fibrosis: initial validation by comparison with histopathologic sampling.Hepatitis delta virus testing, epidemiology and management: a multicentre cross-sectional study of patients in London.The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis.Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries.
P50
Q28258678-12341DC3-446B-4056-9166-40024FEC4A10Q28273143-3EA4768E-24A5-427D-96BD-0CDC26094533Q32097129-F1678A65-296E-4500-BB73-0CABE1B4A83FQ33282214-C71B56BE-93C9-4FFC-880B-FD4F44211374Q33438708-02D9A3E1-3548-475B-B990-3D11EA093E43Q33744789-06131D86-B75A-46CD-9B58-767C7A9970D7Q34028307-6818995D-E327-4D38-8797-D6AA0481E723Q34242413-BBC7A685-038C-4469-BF28-FB23E57CD4FEQ34462234-F014860B-852B-42C8-B6A1-FBC7B1032A54Q34525079-E68D1BC5-7AE3-493F-B72C-AE1A7E1D057CQ34532528-AB93F615-7142-4E4B-B57C-41FFF4B192CAQ34628912-BD3BA09C-6CBC-4224-BB54-2B60A235E86FQ34629141-C1DFE643-C4F6-48F7-9F83-37DA227B5890Q34981143-2DBFD121-CC8D-4E2C-9AA1-6CB42C4E7C9FQ35056461-A655B74D-12CD-4933-9C9D-780B40A8AA32Q35360700-2A7E84DC-DA53-45AE-955F-8953208C974EQ35591846-0AB7C3F6-1763-4EF0-BA50-0C8D2C5BFE9DQ35596037-96E7C396-E395-4352-A842-3BCE42D7B9A7Q35768976-83692BCB-C6F4-4E69-A220-8C698092200BQ35769146-271CB7D2-1AA1-45F3-A456-30B7768FA465Q35855775-3115B3B3-C0AC-4BC0-B950-947F39B7BE9EQ36373907-9C627F2C-DDDE-42D2-BB1C-70880F2C86FFQ36609890-2FB50407-6CFF-4134-AC32-AC8C6FD94869Q36643026-75855755-D5A6-4E6D-B9B0-2731FA5BADE7Q36715064-9B367101-76F3-49C5-95A2-7832DE0322C1Q37014002-A895EDD8-1A91-4C1F-94CF-796375369A80Q37098284-AB90B073-1CE4-40F3-A72F-26085814486EQ37262108-27881DEF-6191-4AD6-9657-53EA7AE1A59EQ37421773-4F7F9425-6111-49DE-8C91-BC68A2481C1AQ37465439-D0B8CF47-8C5E-4FC3-99C5-BA305E80AE7DQ37598020-773A1328-7D15-403A-99B4-CB82720EB10BQ37627015-A04B1117-26C9-45D3-ADE2-D4D801082D36Q37953428-3FDAB2FC-3336-482C-99B7-6A8A0943D97BQ38135774-5DDF7DDC-DA83-4C5D-A9AB-B40EB7E6561FQ38142969-95ACA2E6-91AA-49BB-B103-066DC70A894FQ38430890-32B9FAF6-2671-449A-AE56-B353BE71F71FQ39018820-BA4D1544-A8EC-4935-8277-338092DB2D5BQ39213684-681E4462-6D03-4ABB-856A-3C995FD0CA2EQ40099352-6131CD3E-F181-4709-8BAA-144243392CBAQ40414089-5F3AD1AD-520D-4999-A4B1-AF0946ACCB47
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
William Rosenberg
@ast
William Rosenberg
@en
William Rosenberg
@es
William Rosenberg
@nl
William Rosenberg
@sl
type
label
William Rosenberg
@ast
William Rosenberg
@en
William Rosenberg
@es
William Rosenberg
@nl
William Rosenberg
@sl
prefLabel
William Rosenberg
@ast
William Rosenberg
@en
William Rosenberg
@es
William Rosenberg
@nl
William Rosenberg
@sl
P106
P1153
35374746300
P21
P31
P496
0000-0002-2732-2304